SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
July 19 2022 - 1:30AM
Business Wire
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA),
a leading provider of biopharmaceutical products in China,
announced that a phase III clinical trial for SINOVAC’s inactivated
quadrivalent influenza vaccine was initiated in the Republic of
Chile through a collaboration with the Pontificia Universidad
Católica de Chile (PI Dr. Pablo González). Study results will
provide scientific evidence to support SINOVAC’s influenza vaccine
immunogenicity and protection capacity.
This clinical trial aims to evaluate the immunogenicity and
safety of the quadrivalent influenza vaccine among individuals aged
3 and above. In total, there will be 1,600 volunteers recruited,
half of whom will receive 1 dose of SINOVAC’s inactivated
quadrivalent influenza vaccine, and the other half will receive a
different quadrivalent influenza vaccine commercially available in
Chile. Children aged between 3 and 8 of both groups who haven’t
received any influenza vaccine will receive 2 doses of influenza
vaccine. All of the participants will be observed for 28 days
following the completed inoculation to evaluate vaccine safety. The
upcoming clinical trial in Chile will provide further evidence on
the efficacy and safety of SINOVAC’s quadrivalent influenza
vaccine.
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based
biopharmaceutical company that focuses on the R&D,
manufacturing, and commercialization of vaccines that protect
against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19,
enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD),
hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu),
varicella, mumps, and poliomyelitis.
The COVID-19 vaccine, CoronaVac®, has been approved for use in
more than 60 countries and regions worldwide. The Healive®,
hepatitis A vaccine, passed WHO prequalification requirements in
2017. The EV71 vaccine, Inlive®, is an innovative vaccine
commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain
inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its
H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese
government's vaccination campaign and stockpiling program. The
Company is also the only supplier of the H5N1 pandemic influenza
vaccine, Panflu®, to the Chinese government stockpiling
program.
SINOVAC continually dedicates itself to new vaccine R&D,
with more combination vaccine products in its pipeline, and
constantly explores global market opportunities. SINOVAC plans to
conduct more extensive and in-depth trade and cooperation with
additional countries, and business and industry organizations.
For more information, please see the Company’s website at
www.sinovac.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220718005845/en/
Sinovac Biotech Ltd. PR Team pr@sinovac.com
ICR Inc. Bill Zima U.S.: 1-646-308-1707
william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024